Corvus Pharma Com (CRVS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2019 | 12-2018 | 12-2017 | 12-2016 | 12-2015 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -46,672 | -46,939 | -55,663 | -36,375 | -31,335 |
| Depreciation Amortization | 99 | 239 | 647 | 1,242 | 107 |
| Accounts payable and accrued liabilities | 450 | -1,456 | 1,554 | 518 | 1,240 |
| Other Working Capital | 1,904 | -1,423 | 2,575 | 3,448 | 1,832 |
| Other Operating Activity | 6,898 | 8,591 | 4,675 | 3,310 | 16,828 |
| Operating Cash Flow | $-37,321 | $-40,988 | $-46,212 | $-27,857 | $-11,328 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 3,280 | -29,837 | 85,092 | -40,357 | -90,285 |
| PPE Investments | -25 | -355 | -266 | -2,199 | -1,747 |
| Investing Cash Flow | $3,255 | $-30,192 | $84,826 | $-42,556 | $-92,032 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 24 | 65,270 | 1,442 | 71,358 | 108 |
| Dividend Paid | N/A | N/A | N/A | N/A | 95,569 |
| Other Financing Activity | 0 | 0 | 0 | 0 | -729 |
| Financing Cash Flow | $24 | $65,270 | $1,442 | $71,358 | $94,948 |
| Beginning Cash Position | 39,196 | 45,106 | 5,050 | 4,105 | 12,517 |
| End Cash Position | 5,154 | 39,196 | 45,106 | 5,050 | 4,105 |
| Net Cash Flow | $-34,042 | $-5,910 | $40,056 | $945 | $-8,412 |
| Free Cash Flow | |||||
| Operating Cash Flow | -37,321 | -40,988 | -46,212 | -27,857 | -11,328 |
| Capital Expenditure | -25 | -355 | -266 | -2,199 | -1,747 |
| Free Cash Flow | -37,346 | -41,343 | -46,478 | -30,056 | -13,075 |